Journal
CANCER BIOLOGY & THERAPY
Volume 2, Issue 4, Pages 446-451Publisher
LANDES BIOSCIENCE
DOI: 10.4161/cbt.2.4.479
Keywords
neoplasms; cytotoxicity; membrane proteins; tumor cells; cultured; ligands
Categories
Funding
- FIC NIH HHS [D43 TW00671] Funding Source: Medline
Ask authors/readers for more resources
NKG2D serves as one of the most potent activating receptors for effector lymphocytes in peripheral tissues. Here we report the characterization of Letal, the first human transmembrane NKG2D ligand lacking an immunoglobulin-like alpha-3 ectodomain. Letal is constitutively expressed by a variety of normal tissues, and is up-regulated in tumor cells of different origins. Unlike other NKG2D ligands, Letal mRNA expression progressively decreased after treatment of tumor cells with retinoic acid. Simultaneous T-cell receptor activation and engagement of Letal stimulated proliferation of CD8(+) cells and dramatically increased IL-2 and IFN secretion. In addition, Letal induced the killing of cancer cells by CD8(+) and NK cells. These results suggest that Letal delivers activating signals to NK cells and promotes tumor immune surveillance by inducing the expansion of anti-tumor cytotoxic lymphocytes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available